Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02643550 · ClinicalTrials.gov registry record · Phase 1
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
A Phase 1 study, sponsored by Innate Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 143
- Enrollment target
NCT02643550 is a Phase 1 study that has completed, run by Innate Pharma. The registered enrollment target is 143 participants.
The verdict
NCT02643550, a Phase 1 study, has completed, sponsored by Innate Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 143 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses of Monalizumab given IV in combination with cetuximab in patients who have received prior systemic regimen(s) for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Cohorts expansion will evaluate antitumor activity of monalizumab and cetuximab with or without anti-PD(L)1
Interventions
- BIOLOGICAL Cetuximab
- BIOLOGICAL Monalizumab
- BIOLOGICAL Anti-PD(L)1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2015-12 |
| Est. Completion | 2023-03-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02643550
The ClinicalTrials.gov registry entry for NCT02643550 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innate Pharma, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cetuximab is the first listed.
NCT02643550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02643550 about?
NCT02643550 is a clinical study titled "Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck". The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses of Monalizumab given IV in combination with cetuximab in patients who have received prior systemic regimen(s) for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Cohorts exp...
What is the current status of trial NCT02643550?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 143 participants. The study started on 2015-12. Estimated completion is 2023-03-28.
What interventions are being tested in trial NCT02643550?
The interventions under investigation include: Cetuximab (BIOLOGICAL), Monalizumab (BIOLOGICAL), Anti-PD(L)1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02643550?
This trial is sponsored by Innate Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.